Celcuity is a biotech company based in Minneapolis that focuses on cancer treatments. While their stock price has been trending upwards for several months now, it recently skyrocketed due to an exciting new deal with Pfizer.
Pfizer is one of the world’s foremost pharmaceutical companies right now, and they made an exclusive deal with Celcuity for a breast cancer treatment. Since Pfizer is such a respected company, this deal immediately gives Celcuity some clout.
Celcuity is a smaller company with a market capitalization of US$162m, so it may still be flying under the radar of many institutional investors. Hedge funds do not own Celcuity. The company’s CEO Brian Sullivan is the largest shareholder with 22% of shares outstanding.
Lance Laing, the second-largest shareholder with 10% of shares outstanding, is Top Key Executive, pointing towards strong insider ownership amongst the company’s top shareholders.
Celcuity has had a solid price increase for twelve weeks, gaining 90.7% over this period. Additionally, it’s trading at 89.6% of its 52-week High-Low Range, hinting that it could be on the verge of a breakout.
You do not want to miss this rare event that could make you a fortune
It’s Finally Here…
A brilliant man by the name of Chris Rowe is making a strong prediction…
And it’s important you know about this in time.
For one simple reason…
He has one of the best track records in America when it comes to spotting the massive stock market moves before they happen.
Top headlines you shouldn’t miss
It’s never too late to start saving,
Know someone who’d love the Never Too Late Investor? Be sure to send them to this link so they can get signed up: investinglate.com